Developing new drugs to target Skp2 in cancer treatment
Drug Development of Skp2 PROTACs in Cancer
This study is testing a new type of drug that targets a protein called Skp2, which is linked to the growth of certain cancers, especially prostate cancer that doesn't respond to hormones, to see if it can help shrink tumors and make other treatments work better for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-11085087 on NIH RePORTER |
What this research studies
This research focuses on developing a new class of drugs called PROTACs that target the Skp2 protein, which plays a crucial role in the progression of certain cancers, particularly androgen-independent prostate cancer. By utilizing a novel approach, the researchers aim to enhance the degradation of Skp2, which is often overexpressed in metastatic cancer cells, thereby potentially improving treatment outcomes. The methodology involves creating compounds that can effectively degrade Skp2, which may lead to reduced cancer cell growth and increased sensitivity to existing therapies. Patients may benefit from this innovative treatment strategy if it proves effective in clinical settings.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with androgen-independent prostate cancer or those who have developed resistance to androgen deprivation therapies.
Not a fit: Patients with early-stage prostate cancer or those not resistant to androgen therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with advanced prostate cancer that is resistant to current therapies.
How similar studies have performed: Other research has shown promise in targeting similar pathways in cancer treatment, suggesting that this approach could be a viable and innovative strategy.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Li, Hong-Yu — University of Texas Hlth Science Center
- Study coordinator: Li, Hong-Yu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.